Baxter Healthcare Sa

Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Baxter International Inc.

Ology Bioservices Inc.

Nanotherapeutics, Inc.

Noel Barrett

Friedrich Dorner

Otfried Kistner

Wolfgang Mundt

Johann J Eibl

Manfred Reiter

Heidi Meyer

Artur Mitterer

Yendra Linnau

Marijan Gerencer

Christa Tauer

Hartmut Ehrlich

Falko-Guenter Falkner

Axel Bruehmann

Gerhard Polsler

Wofgang Mundt

Hartmut Erlich

Gerhard Pölsler

The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A.

Production of viral vaccine

The present invention relates to a method for inactivating virus in a sample by treating a virus containing sample with an effective concentration of formalin and by treating the sample with an effective dose of UV light in a flow-through apparatus.

Inactivation of a pathogen in a sample by a treatment with formalin and UV light

The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising

Method for producing viral vaccines

The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen.

Enveloped virus vaccine and method for production

The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.

Inactivated influenza virus vaccine for nasal or oral application

The present invention provides methods of large scale production of Hepatitis A Virus (HAV) on VERO cells bound to microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.

Method of large scale production of Hepatitis A virus

The present invention provides methods of purification of Hepatitis A Virus from the supernatant of an infected cell culture and production of a preparation of purified HAV antigen. The present invention is also directed to an HAV vaccine composition comprising a preparation consisting of purified mature HAV particles in an amount sufficient to induce a protective immune response in a mammal.

Method of production of purified hepatitis a virus particles and vaccine preparation

A method for depleting viral and molecular pathogens in a biological material containing one or several biological substances to be recovered is disclosed, wherein the biological material is admixed with an organic solvent, the solvent-admixed biological material is contacted with an ion exchanger, wherein the pathogens are adsorbed on the ion exchanger material, and at least one of the biological substances to be recovered does not interact or interacts only slightly with the ion exchanger, and the ion exchanger with the pathogens adsorbed thereon is sesparated from the biological material, a virus-depleted preparation of the biological substance being recovered.

Method for depleting viral and molecular pathogens in a biological material

This invention describes an influenza virus vaccine containing an influenza virus antigen obtained from a cell culture, with an influenza virus antigen content between 1 &mgr;g and 5 &mgr;g per dose and aluminum as an adjuvant as well as a method for its preparation.

Influenza virus vaccine composition

Process for disintegrating nucleic acids and preparing biological

Viruses from the family Orthomyxoviridae, particularly influenza virus, can grown in monkey kidney cells, particularly Vero Cells, after passaging the cells in a serum-free or protein-free medium. The use of a proteolytic enzyme, especially trypsin, also aids in the propagation of the virus. The method allows for the virus to be produced to be used in a vaccine.

Production of orthomyxoviruses in monkey kidney cells using protein-free

The invention relates to a method of inactivating lipid-enveloped viruses by means of a non-ionic detergent, and the preparation of a vaccine containing the inactivated virus. The invention further relates to an inactivated virus which is characterized by its structural integrity, in particular the structural integrity of its enveloping proteins, as well as to the use of the inactivated virus for preparing a vaccine.

Growing community of inventors

Klosterneuburg/Weidling, Austria

Noel Barrett